The estimated Net Worth of Charles A. Iii Reinhart is at least $2.38 Millón dollars as of 6 June 2023. Mr. Reinhart owns over 2,607 units of Pacira BioSciences Inc stock worth over $437,138 and over the last 9 years he sold PCRX stock worth over $555,972. In addition, he makes $1,389,740 as Chief Financial Officer at Pacira BioSciences Inc.
Charles has made over 6 trades of the Pacira BioSciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,607 units of PCRX stock worth $100,109 on 6 June 2023.
The largest trade he's ever made was selling 2,648 units of Pacira BioSciences Inc stock on 4 June 2021 worth over $161,634. On average, Charles trades about 692 units every 114 days since 2016. As of 6 June 2023 he still owns at least 33,626 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Reinhart stock trades at the bottom of the page.
Charles A. Reinhart III serves as Chief Financial Officer of the Company., is Chief Financial Officer of the Company. Prior to joining Pacira, he was the Chief Financial Officer at Covis Pharmaceuticals, Inc., a specialty pharmaceutical company, from September 2014 to October 2015. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd., a specialty pharmaceutical company. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. In addition, Mr. Reinhart has previously held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.
As the Chief Financial Officer of Pacira BioSciences Inc, the total compensation of Charles Reinhart at Pacira BioSciences Inc is $1,389,740. There are 6 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Charles Reinhart is 59, he's been the Chief Financial Officer of Pacira BioSciences Inc since 2016. There are 9 older and 12 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon y Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: